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Main point: Nebulized bacteriophages (aerophages) showed promise for the treatment of 
pneumonia due to MRSA; aerophages reduced bacterial loads and lung damage, and when 




















Background The optimal method for delivering phages in the context of ventilator-
associated pneumonia (VAP) is unknown. In the current study, we assessed the utility of 
aerosolized phages (aerophages) for experimental MRSA pneumonia. 
Methods: Rats were ventilated for 4h before induction of pneumonia. Animals received 
either: 1) aerophages; 2) intravenous (IV) phages; 3) a combination of IV and aerophages; 
4) IV linezolid; and 5) a combination of IV linezolid and aerophages. Phages were 
administered at 2, 12, 24, 48 and 72h, and linezolid at 2, 12, 24, 36, 48, 60 and 72h. The 
primary outcome was survival at 96h. Secondary outcomes were bacterial and phage counts 
in tissues, and histopathological scoring of the lungs. 
Results: Aerophages (1) and IV phages (2) each rescued 50% of animals from severe 
MRSA pneumonia (P<0.01 compared to placebo controls). The combination of aerophages 
and IV phages rescued 91% of animals, which was higher than either monotherapy (P<0.05) 
(3). Standard-of-care antibiotic linezolid (4) rescued 38% of animals. Linezolid and 
aerophages (5), however did not synergise in this setting (55% survival).  
Conclusions: Aerosolized phage therapy showed potential for the treatment of MRSA 
pneumonia in an experimental animal model and warrant further investigation for application 
in humans. 












































Mechanically ventilated patients are at risk of contracting ventilator-associated pneumonia 
(VAP) caused by multidrug resistant (MDR) bacterial pathogens [1]. Staphylococcus aureus 
remains a frequent contributor to infection in this setting and despite active programs 
focused on eliminating methicillin-resistant S. aureus (MRSA), it still accounts for 5-15% of 
all cases of VAP [1-4].  
There is a well-recognised need to develop new strategies to combat MDR infections. One 
such approach is the application of bacterial viruses known as phage therapy [5]. We have 
shown previously that intravenous (IV) phage therapy was as effective as standard-of-care 
antibiotics for the treatment of experimental VAP due to MRSA [6]. The findings were 
promising, however phages did not rescue all of the animals nor did it completely eradicate 
MRSA from the lungs. Additionally, phages and antibiotics did not synergise to improve 
outcomes in this setting [6].  
To maximise the potential for phage therapy in the context of lung infections, alternative 
administration strategies warrant investigation. Inhalative therapy using nebulized antibiotics 
has gained clinical acceptance for infections caused by gram-negative bacteria, and current 
guidelines recommend adjunctive inhalative treatments in cases of bacterial persistence and 
antibiotic resistance [7, 8]. Nebulized therapeutics have been shown to concentrate at the 
lung infection site, effectively reduce bacterial loads, and limit systemic exposure and the 
emergence of antibiotic resistance [9, 10]. Proof-of-concept experimental studies 
investigating aerosolized phage therapy revealed efficacy for the treatment of respiratory 
tract infections caused by gram-negative bacteria [11, 12], and a case report detailing the 
treatment of a patient with complex Pseudomonas aeruginosa VAP treated with IV and 
aerosolized phages revealed positive outcomes [13]. Additionally, prophylactic application of 
nebulized phages improved survival of rats in an experimental MRSA VAP model [14]. 



















MRSA pneumonia has been performed. 
Here, the efficacy of aerosolized phages (‘aerophage’) for the treatment of experimental 
MRSA pneumonia was investigated. Aerophages alone, and in combination with IV 
administered therapies (phages and standard-of-care antibiotics) were assessed. Additional 
experiments were performed to improve our understanding of phage pharmacokinetics and 
pharmacodynamics (PK/PD) in the context of lung infection.  
MATERIAL AND METHODS   
MRSA pneumonia model. All animal experiments were approved by the Cantonal 
Committee on Animal Experiments of the State of Bern, Switzerland (approval BE 83/17) 
and according to ARRIVE Guidelines. The model has been described previously [6]. Briefly, 
Wistar rats [Crl:WI(Han), male, 9-10 weeks old, Charles River, Germany] were intubated, 
then ventilated for 4h (10mL/kg tidal volume, 5cmH2O of positive end-expiratory pressure, 50 
breaths/min with FiO2 0.35). This strategy produced mild signs of inflammation and 
pulmonary oedema commonly associated with mechanical ventilation in critical care patients 
[6]. MRSA clinical isolate AW7 was used to establish pneumonia [15]. Following ventilation, 
rats were inoculated via the endotracheal tube with ~1x1010CFU then extubated. Animals 
were monitored for signs of illness using a score system described previously [6, 14], and 
were euthanized with pentobarbital (150mg/kg) as a humane endpoint. Survival at 96h was 
the primary outcome. The secondary outcomes were bacterial and phage loads in the lungs 
and spleen, and histopathological scoring of pneumonia [16]. All secondary outcomes were 
assessed as described previously [6, 14].  
Aerophage procedure. The phage cocktail consisted of equal titers of four genetically 
unique phages called 2003, 2002, 3A and phage K (1.5x1010 plaque forming units [PFU]/ml) 
[6, 14]. The combination of these phages was shown to be effective against 92% of S. 
aureus isolates tested [14], and each phage was capable of infecting MRSA strain AW7. 



















used in humans (Aerogen Solo technology, USA, average particle size 3.1µm) (Fig. 1A). 
Animals were put into an adapted induction chamber and sedated with Sevoflurane (1–3%). 
To achieve optimal drug delivery, sedated spontaneously breathing animals were connected 
to the nebulizer via a full-face mask (Fig. 1A). Each treatment (2ml volume) lasted ~10 
minutes. Three animals were administered aerophages and were immediately euthanized to 
assess phage distribution (PFU) in lung tissue.  
For ‘sham’ animals, MRSA was replaced by 0.15ml 0.9%NaCl following ventilation (0h). At 
2h and 12h, animals received either aerophages (n=3), IV phages (n=4), or a combination of 
both (n=4). Animals were euthanized at 13h and PFU determinations were performed for the 
blood, lung tissue, bronchoalveolar lavage (BAL) fluid, spleen, liver, and kidney. A second 
set of uninfected animals received either placebo (n=5), aerophages (n=6), or IV phages 
(n=5) at 2, 12, 24, 48 and 72h, and were then sacrificed at 96h. Blood was taken for IL-1β 
quantification, as described previously [6]. The placebo consisted of a filtered bacterial 
supernatant that did not contain phages. 
Treatment protocol. In the first round of experiments MRSA infected animals were 
randomized into three groups following inoculation. All animals received both an inhalative 
treatment and an IV treatment each consisting of either phages or placebo. The therapy was 
administered in an investigator/operator blinded manner. Treatment groups were as follows: 
aerophages (n=10); IV phages (0.3ml per treatment, n=10); a combination of both (n=11). 
Each treatment was further applied at 12, 24, 48 and 72h. We knew from previous studies 
that IV phage therapy alone would result in 50% survival [6], and we hypothesized that 
aerophage treatments would increase survival to 99-100%. These estimates (alpha=0.05, 
power 1-β=0.8) required n=11 per group (SigmaPlot 12.0). Two animals were not fit enough 
to be randomized following surgery. Eight animals were included as untreated controls.  
A second round of experiments was performed to assess the additive effects of aerophages 



















or linezolid and aerophages (n=9). Inhalative therapy was administered at 2, 24, 48 and 72h 
after infection and linezolid according to manufacturer’s recommendation twice daily (at 2, 
12, 24, 36, 48, 60 and 72h after infection). Sample sizes were reduced following an interim 
analysis of survival that revealed no synergistic effects.   
Phage resistance determination. The possible emergence of phage-resistant MRSA 
clones following phage treatment was assessed using phage cross streak assays as 
described previously [6].  
In vitro phage-linezolid assessment. An overnight culture of AW7 was diluted in tryptic soy 
broth containing 2mM CaCl2 to reach ~1x10
6CFU/ml. Cultures were supplemented with 
either phages (multiplicity of infection [MOI] of 0.01) or phages and linezolid (10g/ml), then 
incubated at 37° with shaking for 24h. PFU were quantified before (0h) and after treatment 
(24h). The experiment was performed twice in biological triplicates. 
Statistics. Survival of animals was assessed using Kaplan Meier curves and log-rank tests. 
One- or two-way ANOVA (normal distribution), or Kruskal-Wallis tests (non-normal) were 
used. Multiple comparisons were corrected for using Dunnett’s method. Correlations were 
determined using Pearson two-way correlation tests. All analyses were performed using 
GraphPad Prism (v7). Data were considered significant when P<0.05. 
RESULTS 
Aerosolised phages remain active in vitro and in vivo. Phage titres were quantified 
before and after nebulization. On average 93% of phages (SD=1.52%, n=3) were 
recoverable following nebulization. Aerophages were then applied to the lungs of uninfected 
rats to determine bioavailability. On average, 1.4x106PFU/g of phages were recovered. No 
difference in phage titres were detected between cranial and caudal sections, suggesting a 




















Aerophages reduce mortality for animals with established MRSA pneumonia. MRSA 
pneumonia was lethal for untreated controls (Fig. 2A). Treatment with aerophages 
significantly improved survival (50%, P< 0.01, Fig. 2A). Survival was associated with 
reduced bacterial loads in the lungs (Fig. 2B, Fig. S1A), and lower histopathological scoring 
for lung tissue (Fig. 2C), when compared to non-surviving animals.  
Failure to clear MRSA from the lungs was not due to phage resistance. Aerophages did 
not eradicate MRSA from the lungs of animals with pneumonia (Fig. 2B). To determine if 
bacterial persistence in the lung was attributable to phage resistance, the phage 
susceptibility of 100 bacterial colonies taken from the lungs of 10 phage-treated animals was 
tested. Each isolate remained susceptible to the phage cocktail suggesting that the failure to 
eradicate the bacteria was not due to the selection of phage-resistant clones. 
Aerophages localise in the lung, and do not spread to other organs. To explain the 
limited therapeutic efficacy of the aerophages, we performed a series of experiments 
addressing phage PK/PD in uninfected animals. First, we assessed phage distribution in 
various tissues following two rounds of phage treatment (2h, 12h). Aerophages revealed a 
local distribution, highly abundant in lung tissue and BAL fluid, and less abundant in the 
blood, spleen and liver (Fig. 3A). The distribution of aerophages was then compared with 
that of animals treated with an IV bolus of phages using the same treatment regimen. IV 
phages were abundant in the blood, liver and spleen, but less concentrated in the BAL and 
lung tissue when compared to aerophage treatment (~4,000 and ~22–times fewer, 
respectively P<0.0001, Fig. 3A). Combining the two routes resulted in high local and 
systemic distribution of phages (Fig. 3A). 
Aerophages do not induce an inflammatory response. We showed previously that 
repeated IV administration of phages resulted in an elevated inflammatory response, as 
determined by increased levels of the proinflammatory cytokine IL-1β in blood [6]. The 



















phages localised primarily in the lung will produce a dampened systemic inflammatory 
response. In support of this, repeated administration of phages IV (2h, 12h, 24h, 48h, 72h) 
produced an IL-1β response in the blood at 96h that was 11-fold higher than that produced 
by aerophages (P< 0.0001, Fig. 3B). 
Aerophages adjunct to IV phages is an effective treatment for experimental MRSA 
pneumonia. In the context of MRSA pneumonia, while IV phage therapy alone resulted in 
50% survival, the combination of aerophages and IV phages significantly improved survival 
when compared to each monotherapy (91% survival, p<0.05 for each comparison, Fig. 3C).  
There was a significant difference in MRSA counts in the lungs between treatment groups 
(P=0.008, one-way ANOVA, Fig. S1B). When performing pairwise comparisons, the 
average MRSA load in the lungs for animals receiving aerophages or IV monotherapies was 
~100 times lower when compared to placebo controls; however this was not statistically 
significant (P=0.226 and 0.152 respectively, Fig. S1B), likely owing to the large difference 
between non-surviving and surviving animals in each group (Fig. S1A). In contrast, the 
combination aerophages and IV treatment group which had the best survival animals, had 
~1,000-times less MRSA in the lungs compared to untreated controls, and this difference 
was significant (P=0.005, Fig. S1B). When compared with aerophages alone, reduced lung 
bacterial densities associated with combination IV phages and aerophages were not 
statistically different (P=0.340). No statistical differences in MRSA counts in the spleen were 
detected between treatments (P=0.512, Kruskal-Wallis test, Fig. S1C). 
Aerophages adjunct to IV linezolid did not improve survival for rats with experimental 
MRSA pneumonia. Given the efficacy of combined systemic and local phage therapy (Fig. 
3C), we next evaluated the aerophages/linezolid IV combination. While IV linezolid alone 
rescued 37.5% of animals from lethal pneumonia, the combination with aerophages did not 
synergise in vivo. No improved survival (Fig. 4A), nor improved bacterial clearance (Fig. 



















between phage and bacterial loads in the lungs for animals treated with aerophages alone 
(Fig. 4B). In contrast, no correlation was observed for animals treated with the combination 
(Fig. 4B). Additionally, phages were detected in the spleen for half of the animals treated 
with aerophages, but not detected in any of those that received the combination (P=0.033, 
Fischer’s exact test, Fig. S1E), suggesting linezolid may have a detrimental effect on phage 
amplification. To lend support to these in vivo associations, MRSA was exposed to phages, 
linezolid, or a combination of both, in vitro. In the absence of linezolid, phages increased by 
~106 PFU/ml fold after 24h. In contrast, the addition of linezolid abolished phage 
amplification at the tested MOI of 0.01 (Fig. 4C).  
DISCUSSION 
We systematically evaluated the utility of nebulized phages for the treatment of experimental 
MRSA pneumonia in rats. The key findings of this study, presented in Supp. Tab. 1, are as 
follows: (i) aerophages administered directly to the lungs retained their activity, and 
remained localised at high concentration within lung tissue following application; (ii) 
aerophages alone improved survival for animals with MRSA pneumonia, and when 
combined with IV phages rescued almost all of the animal subjects; and (iii) aerophages 
adjunct to IV linezolid did not synergise in this experimental setting.  
IV phage therapy improved survival for animals with MRSA pneumonia, supporting previous 
findings [6]. IV therapy, however, did not rescue all animals, or eradicate MRSA from the 
lungs. We postulated that IV therapy failed in non-survivors due to poor PK/PD, including 
limited penetration into the lung, and failure of the phages to overcome the clearing effects of 
the blood [17]. Inhalative therapy has shown potential to overcome the caveats of IV therapy 
in the context of pneumonia; at least for antibiotics, high concentrations can be achieved at 
the site of infection that are not tolerable using systemic application, and this is associated 
with reduced systemic side effects such as toxicity and antibiotic resistance development at 



















compared with IV delivery, aerophages were more concentrated in the lungs, as 
demonstrated by high titres in the BAL, and they were not associated with systemic side 
effects such as a heightened proinflammatory response or the emergence of phage 
resistance. 
Aerophages, however, did not rescue all of the animals from MRSA pneumonia. It is 
possible that aerophage treatment failure may have occurred due to insufficient penetration 
of phages to poorly aerated areas of lung parenchyma; a hypothesis that is worthy of further 
investigation. It is also possible that, given the localised distribution of aerophages in the 
lung, mortality for non-surviving animals was due to infection metastasis. In humans, 
bacteraemia appears to be a major predictor of mortality for patients with VAP [18, 19]. 
Indeed, in the experimental model of pneumonia used in this study, mortality was 
significantly associated with the presence of MRSA in the spleen, which we use as a proxy 
for systemic spread (Fig. S1A). Combining a localized therapy (aerophages) with systemic 
therapy (IV phages) improved survival compared to either therapy alone, and was 
associated with the best microbiological outcomes in the lungs and spleen.  
Glycopeptides and linezolid are the first line treatments for MRSA pneumonia [20]. We 
chose linezolid for assessing aerophage-antibiotic combination therapy because unlike for 
glycopeptides (teicoplanin), it synergised with phages in vitro [6]. Combined linezolid and 
aerophages therapy in the pneumonia model did not result in improved outcomes compared 
to either therapy alone. It is apparent that phage amplification (termed ‘autodosing’ [21]), is 
important for successful treatment of MRSA pneumonia. For aerophages alone, there was a 
positive correlation between bacteria and phage counts in the lung, suggesting bacterial 
host-dependent phage amplification, which was not observed for animals receiving adjunct 
linezolid. Linezolid is a bacteriostatic agent that inhibits protein synthesis [22]. Phages rely 
on bacterial machinery to replicate, and the action of linezolid impaired phage amplification.  



















antagonisms, depending on the concentration of each agent [23]. Previously, we showed 
synergy between linezolid and phages using a checkerboard assay [6]. In contrast, when 
simulating the PK parameters of the pneumonia model in vitro (Linezolid 10 µg/ml, based on 
a Cmax of ~15µg/ml [24], and phage MOI of 0.01), linezolid drastically impaired phage 
amplification, which may explain the poor treatment outcomes for the aerophage-linezolid 
combination therapy. Future studies are required to further understand the interaction 
between phages and antibiotics, in order to exploit synergies, and avoid antagonisms. 
The model used in this study has important limitations. It is rapidly lethal, and animals 
require treatment shortly after inoculation (2h), which does not accurately reflect the clinical 
scenario. The model also relies on a high dose of bacteria to establish a reproducible 
infection (1x1010CFU). In order to achieve a reasonable MOI for therapy, high phage doses 
were administered (3x1010PFU per treatment). In contrast, in the two published human case 
studies using nebulized phages, each patient was administered 1.5x1010PFU per treatment 
[13, 25], which is considerably lower when the size of the subject is accounted for. Thus, it is 
difficult to extrapolate optimal phage dosing as it pertains to humans using the current rodent 
model. Further studies are warranted addressing aerophage dosing and lung distribution 
using larger experimental animals such as pigs [26].  
In summary, aerophage therapy has shown potential for the treatment of pneumonia due to MRSA, 
and when combined with systemic phage therapy, improved animal survival and reduced MRSA 
burdens in tissues. Results from this translational study pave the way for future placebo-controlled 
trials assessing the safety and efficacy of adjunct aerophages for the treatment of VAP due to MRSA 
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Figure 1. Nebulized delivery of phages to the lungs of rats. (A) Administration of phages aerosolized 
via an Aerogen® Solo vibrating mesh nebulizer used in humans and generating particles of 3.1µm 
average size. (B) Phage titres in cranial and caudal sections of lungs in uninfected animals 
immediately following one aerophage treatment. PFU, plaque forming units.  
 
Figure 2. Aerosolized phage treatment of rats with MRSA pneumonia. (A) Kaplan-Meier survival 
curves for rats with untreated MRSA pneumonia (n=8), and those treated with aerophages (n=10). 
Significance was determined by log-rank test. (B) MRSA bacterial loads in the lungs of rats with 
MRSA pneumonia. CFU; colony forming units. (C) Histopathological score was determined for the 
lung of rats with MRSA pneumonia. For each panel, ‘AERO’ (blue) represents aerophage treatment. 
Secondary endpoints (CFU, histology) were assessed immediately after an animal succumbed to 
infection (represented by crosses), or at the end of the 96 hour trial (represented by closed circles). 
For B and C, significance was assessed using one-way ANOVA with corrections for multiple 
comparisons using Tukey’s method. ** P<0.01; **** P<0.0001.    
 
Figure 3. PK/PD and treatment efficacy comparisons for uninfected animals treated with 
aerophages, IV phages, or the combination of both. (A) Animals received two doses of phages (2h, 
and 12h after ventilation) and were sacrificed at 13h. Animals received either aerophages (AERO, 
n=3), IV phages (IV, n=4), or a combination of each (AERO+IV, n=4) Phage loads were quantified from 
the blood, bronchoalveolar lavage (BAL) fluid, and various organs. Statistical differences were 
determined using two-way ANOVA with corrections for multiple comparisons using Tukey’s method, 
**** P<0.0001. PFU, plaque forming units. (B) Additional uninfected animals received repeated 



















and IL-1β was compared to baseline (0h) for each animal. Untreated animals (n=5) were included as 
controls. Statistical significance was determined using one-way ANOVA with multiple comparison 
correction using Tukey method, **** P<0.0001. (C) Kaplan-Meier survival curves for rats with MRSA 
pneumonia treated with aerophages (n=10), IV phages (n=11), or a combination of each (n=11). 
Significance was determined by log-rank test, * P<0.05. 
 
Figure 4. Combination linezolid and aerophage therapy for the treatment of MRSA pneumonia. (A) 
Kaplan-Meier survival curves for rats with MRSA pneumonia treated with aerophages (‘AERO’, 
n=10), IV linezolid (‘LZD_IV’, n=8), or a combination of each (‘AERO+LZD_IV’, n=9). Significance was 
determined by log-rank test; no differences were significant. (B) Correlation analysis of bacteria and 
phage loads in the lung of animals treated with either aerophages or aerophages and linezolid. CFU, 
colony forming units (CFU) and plaque forming units (PFU) were assessed immediately after an 
animal succumbed to infection (represented by crosses), or at the end of the 96 hour trial 
(represented by closed circles). Pearson two-way correlation tests were used to determine statistical 
significance. (C) MRSA strain AW7 was exposed to phages in vitro (multiplicity of infection 0.01), 
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